

First Generic of Advair Diskus[®] Available

In January 2019, the U.S. Food and Drug Administration (FDA) approved the first generic version of blockbuster inhaler Advair Diskus[®] (fluticasone propionate and salmeterol inhalation powder). The product became commercially available in February and carries the name Wixela Inhub[®].

Mylan received approval for the product, and it is available in three strengths containing fluticasone propionate/salmeterol: 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg. The average wholesale price (AWP) per 30-day inhaler is \$361.44, \$449.08 and \$590.63, respectively. In contrast, the AWP per Advair Diskus inhaler is \$380.46, \$472.72 and \$621.72, respectively.

Wixela Inhub (fluticasone propionate and salmeterol inhalation powder) is taken by oral inhalation twice daily and approved for the following uses:

- ▶ Treatment of asthma in patients 4 years of age and older who are not sufficiently controlled on long-term asthma control medications or whose condition requires treatment with both an inhaled corticosteroid and a long-acting beta agonist
- ▶ Maintenance treatment of chronic obstructive pulmonary disease (COPD)
- ▶ Reduction of COPD exacerbations in individuals with a history of exacerbations

Wixela Inhub has met the FDA requirements to be deemed therapeutically equivalent to the Advair Diskus and can be substituted as the generic for Advair Diskus at the pharmacy. Other generic versions of the Advair Diskus are under development and expected to be approved in the coming years.

For additional details, view the manufacturer's [press release](#) or FDA [news release](#).

References

1. FDA approves first generic Advair Diskus. FDA News Release. <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm630151.htm>. Published January 30, 2019. Accessed January 31, 2019.
2. FDA approves Mylan's generic of Advair asthma treatment. Reuters. <https://www.reuters.com/article/us-mylan-nl-fda/fda-approves-mylans-generic-of-advair-asthma-treatment-idUSKCN1PO2Z7>. Published January 30, 2019. Accessed January 31, 2019.
3. Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair. FiercePharma. <https://www.fiercepharma.com/pharma/mylan-finally-crosses-finish-line-long-awaited-generic-glaxosmithkline-s-advair>. Updated January 30, 2019. Accessed January 31, 2019.
4. Lynch M. Mylan's generic to cost 70% less than Advair. In-PharmaTechnologist.com. <https://www.in-pharmatechnologist.com/Article/2019/02/12/Advair-generic-set-at-third-of-a-cost-than-competition>. Updated February 12, 2019. Accessed February 16, 2019.